Keith Friedenberg is a Gastroenterology physician. OpenAlex indexes 22 publications with 1,287 citations (h-index 12).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
8877 Mentor Ave
Mentor, OH 440606211
Telephone
440-205-1225Provider last certified this registry record 16 Feb 2026.
Industry payments
41 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Phathom Pharmaceuticals, Inc.Program year202537 payments$21,997openpaymentsdata.cms.gov ↗
- ABBVIE INC.Program year202518 payments
- Aimmune Therapeutics, Inc.Program year202513 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
87.6%Proton pump inhibitor54.1%Omeprazole57%Pantoprazole Sodium42%Esomeprazole Magnesium1%Part D<11 patientsAnticholinergic12.9%Dicyclomine Hcl100%Part D≥147 patients+ 13 more classes in this area
Cardiovascular
6.3%Bile Acid Sequestrant5.2%Colestipol Hcl67%Cholestyramine21%Colesevelam Hcl13%Part D<11 patientsAldosterone antagonist (MRA)0.7%Spironolactone100%Part D<11 patients+ 1 more class in this area
Respiratory
3.9%Corticosteroid3.4%Budesonide Dr72%Budesonide Ec28%Part D≥19 patientsPhenothiazine0.5%Promethazine Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI
Infectious Diseases and Therapy
2024 - Correction to: Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI
Infectious Diseases and Therapy
2024 - Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study
The Lancet. Gastroenterology & hepatology
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Josep M. Llovet
Institució Catalana de Recerca i Estudis Avançats
Joseph J.�Y. Sung
Nanyang Technological University
Neeraj Bhala
The Royal Melbourne Hospital
Jordi Bruix
Hospital Clínic de Barcelona
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”